TURTLE
Research type
Research Study
Full title
A Randomised Controlled Trial of Secukinumab Versus Adalimumab for the Treatment of Juvenile Idiopathic Arthritis (JIA) Associated Uveitis or chronic anterior uveitis using a Bayesian Design
IRAS ID
1006319
Contact name
Athimalaipet Ramanan
Contact email
Sponsor organisation
University Hospitals Bristol and Weston NHS Foundation Trust
Eudract number
2022-003068-26
ISRCTN Number
ISRCTN12427150
Research summary
The aim of the study is to see which treatment (Adalimumab or Secukinumab) is better for treating patients who suffer with Juvenile Idiopathic Arthritis (JIA) and Uveitis or chronic anterior Uveitis. JIA is the most common rheumatic disease in children. Around 1 in 1000 children in the UK develops JIA per year. Of these, 15-25% are at risk of inflammation of the uvea in the eye (known as uveitis). The majority of children with JIA are treated with a medication called methotrexate but over 40% need more medication to control uveitis. Adalimumab has shown to work together with methotrexate for controlling uveitis in JIA patients but for 27% of patients it didn't work. Secukinumab has shown to work in treating adults with uveitis. The study will aim to recruit 50 patients aged 2-18 years old from around 12 hospitals across the UK. Participants will be involved in the study for 24 weeks of treatment and then 72 weeks follow up, if they are getting better with study treatment at 24 weeks then they may be able to carry on taking study treatment in follow-up. Patients will receive an ophthalmology and rheumatology review, be asked to complete some questionnaires, complete routine assessments (pregnancy test, urinalysis, physical examination, vital signs, height and weight, routine blood samples), complete a treatment diary and provide optional biobank samples.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
22/NW/0366
Date of REC Opinion
18 Jan 2023
REC opinion
Further Information Favourable Opinion